Sichuan Kelun-Biotech Biopharmaceutical (SKB BIO-B) saw its shares surge 7.36% in the intraday session on Wednesday, outperforming the broader market. The rally was fueled by the company receiving marketing authorization from China's National Medical Products Administration (NMPA) for its breast cancer drug.
The approved drug, sacituzumab tirumotecan (sac-TMT), is designed to treat advanced or metastatic triple-negative breast cancer (TNBC) in adult patients who have already undergone at least two prior systemic therapies, including one for advanced or metastatic disease. The drug targets TROP2 using an antibody-drug conjugate and is intended for TNBC cases that cannot be surgically removed.
The positive regulatory development has bolstered investor confidence in SKB BIO-B's prospects, as the company can now commercialize the breast cancer drug in China's sizable healthcare market. Analysts will be closely monitoring the drug's market performance and potential revenue contribution to the company's financials.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。